



August 23, 2024

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

## **Notice Concerning Termination of Exclusive Sales Rights Agreements for HGF Gene Therapy Product "Collategene"**

AnGes announces that the "Exclusive Distribution License Agreement in Japan" released on June 23, 2015 and the "Exclusive Distribution License Agreement in the United States" released on October 24, 2012 for the HGF gene therapy product "Collategene" between AnGes and Mitsubishi Tanabe Pharma, respectively the two agreements will expire on November 1, 2024 and February 1, 2025, respectively.

As announced in a release on June 24, 2024, we filed an application in May 2023 for the removal of conditions for "Collategene," which had received manufacturing and marketing approval with conditions and a time limit, but withdrew this application, resulting in the expiration of the approval and the termination of sales in June 2024. Under these circumstances, we have agreed with Mitsubishi Tanabe Pharma Corporation to terminate the above agreement.

We will continue to strive for sustainable growth and further enhancement of its corporate value to meet your expectations.

This event will have no impact on our consolidated financial results. We will promptly announce any further events that should be disclosed in the future.

(Note) This document has been translated from the Japanese original for reference purposes only.  
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.